Webcast to Begin at 10:30 AM PDT, 1:30 PM EDT on August 29, 2011
EMERYVILLE, Calif., Aug. 24, 2011 (GLOBE NEWSWIRE) -- NovaBay® Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective Aganocide® compounds for the local non-systemic treatment and prevention of antibiotic-resistant infections, announces that Ron Najafi, Ph.D., Chairman and Chief Executive Officer, will deliver a corporate presentation at The 2011 Southern California Investor Conference to be held at the Island Hotel Newport Beach on August 29, 2011. The presentation is scheduled for 10:30 AM PDT / 1:30 PM EDT, and a webcast can be accessed through the following link: http://events.powerstream.net/002/00623/20110829SCICnovaBay/
Dr. Najafi will discuss the current status of NovaBay's NeutroPhase® and Aganocide compounds, which are novel, broad-spectrum, fast-acting, antimicrobial molecules designed to mimic the body's defense against infection. When applied topically, these compounds maintain biological activities while demonstrating improved solution stability over naturally occurring antimicrobial molecules. NovaBay recently provided an update on its four business units, and Dr. Najafi will highlight the following at the conference:
-
Urology: Phase 2 UCBE trial has commenced in permanently catheterized spinal cord injury (SCI) patients at multiple clinical centers in the U.S.; results are expected in the 2nd half of 2011.
-
Dermatology: Impetigo indication has been successfully partnered with Galderma, the world's leading dermatology company. An Investigational New Drug application (IND) has been filed with the FDA and NovaBay received clearance to conduct formal Phase 1 studies. NovaBay will transfer the IND to Galderma and Galderma is expected to commence a multi-country 400-patient Phase 2b clinical trial in Q4-2011 with data expected in the 2nd half of 2012.
-
Ophthalmology: The company anticipates continuing the development of treatment for viral conjunctivitis (pink eye) based upon encouraging results demonstrated in the recently concluded Phase 2 study. The company expects to initiate a re-designed Phase 2b trial in 2012.
- Hospital Infection: NovaBay's FDA 510(k) cleared NeutroPhase product for wound healing is in manufacturing stages and is expected to be available for commercial launch in 1st half of 2012 to the six million patients suffering from chronic non-healing wounds such as diabetic, pressure and venous stasis ulcers.
About The Southern California Investor Conference
The Southern California Investor Conference highlights the wealth of growth companies located in the region including world recognized life science, technology, media and real estate/financial companies. Officers from over 50 of Southern California's leading companies will present a corporate update and business insights to attendees.
To arrange a meeting with management, please contact Adam Holdsworth at the Investor Relations Group, 212-825-3210, or e-mail adam@investorrelationsgroup.com.
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary and patented Aganocide compounds. These are novel, synthetic anti-infectives with activity against bacteria, fungi and viruses, and are being developed to treat and prevent a wide range of local, non-systemic infections with a low likelihood of developing bacterial resistance.
NovaBay is focusing its technology on four distinct therapeutic areas: dermatology, ophthalmology, urology and hospital infections. In dermatology, the focus is on developing NVC-422 gel for impetigo. NovaBay has the advantage of being partnered with Galderma, the leading dermatology company in the world. In ophthalmology, the goal is to develop an eye drop for conjunctivitis, also known as "Pink Eye." In urology, NovaBay aims to reduce the incidence of urinary catheter blockage and encrustation (UCBE) and the potential for urinary tract infections with an irrigation solution containing NVC-422. In hospital infection, NovaBay is targeting the six-million-patient market of chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers with its proprietary anti-infective solution, NeutroPhase, which has received two 510(k) clearances from the Food and Drug Administration. For additional information, visit www.novabaypharma.com.
Cautionary Information Regarding Forward-Looking Statements
This release contains forward-looking statements, which are based upon NovaBay's current expectations, assumptions, projections and beliefs. Many of these statements are identified by the use of words denoting future events, such as "expect," "anticipate," "plan," "will" and variations of such words. These forward-looking statements include, but not limited to, NovaBay's plans and expectations regarding ongoing and future clinical trials, the timing of commencement and receiving results of clinical trials and the timing of the commercial launch of NeutroPhase. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. Factors that might cause such differences include, but are not limited to: the risk that negative results from development programs could preclude Galderma from providing additional funding to NovaBay; the risk of unexpected delays in the regulatory process may delay the commencement or completion of clinical trials; inherent risks and uncertainties relating to difficulties or delays in conducting clinical trials; the inherent uncertainty of patent protection for the company's intellectual property or trade secrets; the risks that results obtained in animal models may not be obtained in humans; as well as other risks relating to NovaBay and its Aganocide compounds detailed in NovaBay's Quarterly Report on Form 10-Q, under the caption "Risk Factors" in Item 1A of Part II of that report, which was filed with the Securities and Exchange Commission on August 10, 2011. The forward-looking statements in this press release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.